Robert W. Baird Cuts Cooper Companies (NASDAQ:COO) Price Target to $107.00

Cooper Companies (NASDAQ:COO - Free Report) had its target price reduced by Robert W. Baird from $117.00 to $107.00 in a research report report published on Friday morning,Benzinga reports. They currently have an outperform rating on the medical device company's stock.

Several other research analysts have also weighed in on COO. Wells Fargo & Company lifted their target price on Cooper Companies from $115.00 to $118.00 and gave the stock an "overweight" rating in a report on Friday, December 6th. Morgan Stanley cut their price objective on Cooper Companies from $104.00 to $102.00 and set an "equal weight" rating on the stock in a report on Friday, December 6th. Needham & Company LLC reissued a "hold" rating on shares of Cooper Companies in a research note on Friday. Citigroup dropped their target price on shares of Cooper Companies from $115.00 to $110.00 and set a "buy" rating on the stock in a report on Friday. Finally, StockNews.com cut shares of Cooper Companies from a "buy" rating to a "hold" rating in a report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $111.89.

Remove Ads

Cooper Companies Trading Up 1.4 %

Shares of NASDAQ:COO traded up $1.14 during midday trading on Friday, hitting $81.03. The company had a trading volume of 3,370,815 shares, compared to its average volume of 1,725,305. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32. Cooper Companies has a 12 month low of $78.43 and a 12 month high of $112.38. The firm has a fifty day simple moving average of $92.14 and a 200 day simple moving average of $99.34. The stock has a market cap of $16.17 billion, a price-to-earnings ratio of 41.55, a PEG ratio of 2.25 and a beta of 1.02.

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The firm had revenue of $964.70 million for the quarter, compared to analysts' expectations of $981.25 million. On average, analysts predict that Cooper Companies will post 3.98 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Cooper Companies during the 4th quarter worth about $17,392,000. Jefferies Financial Group Inc. increased its position in shares of Cooper Companies by 138.9% in the fourth quarter. Jefferies Financial Group Inc. now owns 48,514 shares of the medical device company's stock valued at $4,460,000 after acquiring an additional 28,204 shares during the last quarter. Mackenzie Financial Corp raised its holdings in Cooper Companies by 12.4% during the fourth quarter. Mackenzie Financial Corp now owns 19,910 shares of the medical device company's stock worth $1,830,000 after acquiring an additional 2,193 shares in the last quarter. Forum Financial Management LP boosted its position in Cooper Companies by 107.3% during the fourth quarter. Forum Financial Management LP now owns 3,840 shares of the medical device company's stock valued at $353,000 after purchasing an additional 1,988 shares during the last quarter. Finally, Castlekeep Investment Advisors LLC acquired a new position in Cooper Companies during the fourth quarter valued at approximately $685,000. Institutional investors and hedge funds own 24.39% of the company's stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.